Daniel S. Levine

Daniel S. Levine is editor of Rare Daily. You can contact him by sending email to editor@globalgenes.org

FDA Grants Rare Pediatric Disease Designation to Albireo’s Candidate for Rare Liver Disease
Rare Daily Staff The U.S. Food and Drug Administration granted Albireo Pharma’s lead candidate A4250 Rare Pediatric Disease designation… Continue Reading
Alexion and Complement Pharma Form Partnership to Co-Develop Complement Inhibitor for Neurodegenerative Disorders
Rare Daily Staff Alexion Pharmaceuticals entered into a partnership with Complement Pharma to co-develop the preclinical C6 complement… Continue Reading
DOJ Says It Won’t Defend ACA in Latest Challenge to Constitutionality—Threatens Protections on Pre-Existing Conditions
Rare Daily Staff The U.S. Department of Justice said it agrees with plaintiffs in a lawsuit that seeks to throw out as unconstitutional the… Continue Reading
BridgeBio Pharma Acquires Late-Stage Therapy for Ultra-Rare Disorder from Alexion
Rare Daily Staff BridgeBio Pharma said it has entered into an agreement with Alexion Pharmaceuticals to acquire ALXN1101, a synthetic… Continue Reading
Hacking Rare Disease
As a teenager, Bill Paseman worked with his father in the refineries around the Houston area. He remembers remarking to him at the time that… Continue Reading
Gene Therapy Developer MeiraGTx Raises $75 Million in IPO
Rare Daily Staff MeiraGTx, which is developing gene therapies to treat diseases of the eye, salivary gland, and central nervous system,… Continue Reading
FDA Approves Genentech’s Rituxan for Rare Autoimmune Condition
Rare Daily Staff The U.S. Food and Drug Administration approved Genentech’s Rituxan for adults with moderate to severe pemphigus vulgaris,… Continue Reading

Follow us on Twitter